Rouen Normandy University   Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3 Phase 4
Founded: Rouen France (1602)

Organization Overview

First Clinical Trial
1997
NCT00120588
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

CHU de Rouen | CHU de ROUEN | CHU de Rouen - Accueil | CHU-Hôpitaux de Rouen - Hôpital de Bois-Guillaume, Service de pneumologie, Bois-Guillaume, France | CHU-Hôpitaux de Rouen - Service de pneumologie, Hôpital de Bois-Guillaume, Rouen, France ; UPRES EA 3830, Institut de Recherche et d'Innovation Biomédicale de Haute-Normandie, Université de Rouen, Rouen, France | chu Rouen | CHU Rouen | clinique dermatologique du chu de Rouen | CRFDP (University of Rouen) | Departement of Anesthesia, University Hospital, Rouen | HOPITAL CHARLES NICOLLE - ROUEN | HOPITAL CHARLES NICOLLE, ROUEN | HOPITAL CHARLES NICOLLE - ROUEN CEDEX | Hôpital Claude-Huriez | HOPITAL CLAUDE HURIEZ- LILLE CEDEX | Normandie University, UNIROUEN, UPRES EA 3830, Haute Normandie Research and Biomedical Innovation, Rouen, France ; Pulmonary, Thoracic Oncology and Respiratory Intensive Care Department, Rouen University Hospital, Rouen, France | Rouen (FR), University College Hospital | Rouen university Hospital | Rouen University Hospital | UH Rouen | UH-Rouen | UMR_S 1077 Inserm-EPHE-Normandie Université | University hopsital of Rouen | University Hospital of Rouen | University Hospital of Rouen, France: | University Hospital, Rouen | University of Rouen | University of Rouen Normandie

Active Ingredients

Drugs in Phase 4 Trials (17)

89zr-bevacizumab (1 trial)

adalimumab (humira) (1 trial)

aprepitant (Emend) (2 trials)

cinacalcet (sensipar) (1 trial)

clobetasol (dermovate) (1 trial)

Diatrizoate (gastrografin) (1 trial)

isoflurane (forane) (1 trial)

l-glutamine (3 trials)

magnesium oxide (1 trial)

midazolam (versed) (2 trials)

omalizumab (xolair) (1 trial)

propofol (diprivan) (1 trial)

rasagiline (azilect) (1 trial)

rituximab (rituxan) (9 trials)

ropivacaine (naropin) (5 trials)

sevoflurane (ultane) (1 trial)

tacrolimus (prograf) (2 trials)

Drugs in Phase 3 Trials (51)

abobotulinumtoxinA (Dysport) (1 trial)

acetylsalicylic acid (aspirin) (1 trial)

anakinra (Kineret) (1 trial)

apremilast (otezla) (1 trial)

autologous skeletal myoblast (1 trial)

baricitinib (olumiant) (1 trial)

ciclopirox (loprox) (1 trial)

cisplatin (platinol) (2 trials)

clarithromycin (biaxin) (1 trial)

cyclophosphamide (cytoxan) (2 trials)

cyclosporine (sandimmune) (1 trial)

cyproviron (1 trial)

denosumab (prolia) (1 trial)

dexmedetomidine (precedex) (1 trial)

doxorubicin (Doxil) (1 trial)

eculizumab (Soliris) (1 trial)

emtricitabine (emtriva) (1 trial)

enoxaparin (lovenox) (1 trial)

esomeprazole (nexium) (1 trial)

estradiol (progynon depot) (1 trial)

ethinyl estradiol (Estinyl) (1 trial)

febuxostat (uloric) (1 trial)

ferric carboxymaltose (Injectafer) (1 trial)

gemcitabine (gemzar) (1 trial)

human fibrin (Tisseel) (1 trial)

immune globulin (human) (Gamastan) (1 trial)

ivabradine (corlanor) (1 trial)

lactose (1 trial)

lidocaine (xylocaine) (1 trial)

loxapine (loxitane) (1 trial)

medicinal charcoal (1 trial)

metronidazole (flagyl) (2 trials)

morphine (2 trials)

naltrexone (revia) (2 trials)

nicotinamide (1 trial)

piperacillin (pipracil) (1 trial)

procaine benzylpenicillin (novocaine) (1 trial)

remifentanil (ultiva) (2 trials)

rimabotulinumtoxinB (Myobloc) (2 trials)

sargramostim (leukine) (1 trial)

secukinumab (cosentyx) (1 trial)

serogroup B meningococcal vaccine (Bexsero) (1 trial)

sildenafil (viagra) (1 trial)

sirolimus (rapamune) (1 trial)

sodium chloride (3 trials)

tazobactam (Zosyn) (1 trial)

tenofovir (viread) (1 trial)

terlipressin (Terlivaz) (1 trial)

tetracycline (tetrex) (1 trial)

triptorelin (Trelstar) (1 trial)

vinblastine (velban) (1 trial)

Drugs in Phase 2 Trials (18)

autologous stromal vascular fraction (1 trial)

bosentan (tracleer) (1 trial)

caplacizumab (cablivi) (1 trial)

carboplatin (paraplatin) (1 trial)

clavulanate (Augmentin) (1 trial)

dapagliflozin (farxiga) (1 trial)

etoposide (vepesid) (2 trials)

fentanyl (Innovar) (1 trial)

fludeoxyglucose f-18 (1 trial)

fluorothymidine (1 trial)

fluorouracil (efudex) (1 trial)

hydroxychloroquine (plaquenil) (1 trial)

irinotecan (Camptosar) (2 trials)

leucovorin (1 trial)

melphalan (alkeran) (1 trial)

nifedipine (procardia) (1 trial)

oxaliplatin (eloxatin) (1 trial)

vincristine (oncovin) (1 trial)

Drugs in Phase 1 Trials (3)

apixaban (eliquis) (1 trial)

glucose (1 trial)

red blood cells (1 trial)

Drugs in Other Trials (21)

18f-2-fluoro-2-deoxy-d-glucose fluorodeoxyglucose (FDG) (1 trial)

agalsidase alfa (Replagal) (1 trial)

arginine (1 trial)

beetroot juice (1 trial)

bq-123 (1 trial)

bq 788 (1 trial)

carbamazepine (tegretol) (1 trial)

citrulline (1 trial)

eslicarbazepine acetate (aptiom) (1 trial)

gadobenate (Multihance) (1 trial)

hymenoptera venom (1 trial)

icosapent ethyl (vascepa) (1 trial)

lactobacillus delbrueckii (1 trial)

lamotrigine (lamictal) (1 trial)

leucine (1 trial)

lysine (1 trial)

octreotide (sandostatin) (1 trial)

oxcarbazepine (trileptal) (1 trial)

oxygen (2 trials)

valproic acid (depakene) (1 trial)

valpromide (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acute Kidney Injury (Phase 3)

Acute Pain (Phase 3)

Adenocarcinoma (Phase 2)

Alopecia (Phase 3)

Alopecia Areata (Phase 3)

Anorexia (Phase 3)

Anorexia Nervosa (Phase 3)

Antiphospholipid Syndrome (Phase 2)

Arteritis (Phase 3)

Arthritis (Phase 4)

Arthritis, Rheumatoid (Phase 4)

Autoimmune Diseases (Phase 3)

Brain Ischemia (Phase 4)

Carcinoma, Ductal (Phase 2)

Carcinoma, Non-Small-Cell Lung (Phase 2)

Colonic Neoplasms (Phase 3)

Congenital Abnormalities (Phase 4)

Dermatitis (Phase 3)

Dermatitis, Seborrheic (Phase 3)

Diabetes Mellitus (Phase 2)

Drug Hypersensitivity (Phase 3)

Emergencies (Phase 3)

Endometriosis (Phase 3)

Esophageal Neoplasms (Phase 2)

Fecal Incontinence (Phase 3)

Gastrointestinal Hemorrhage (Phase 3)

Giant Cell Arteritis (Phase 3)

Hemophilia A (Phase 3)

Hemorrhage (Phase 4)

Hyperparathyroidism (Phase 4)

Hypersensitivity (Phase 3)

Hypertension (Phase 2)

Intestinal Obstruction (Phase 4)

Intracranial Hemorrhages (Phase 4)

Ischemia (Phase 4)

Leukomalacia, Periventricular (Phase 4)

Lung Neoplasms (Phase 2)

Muscular Dystrophies (Phase 3)

Muscular Dystrophy, Oculopharyngeal (Phase 3)

Obesity (Phase 3)

Obesity, Morbid (Phase 3)

Parkinson Disease (Phase 4)

Pemphigoid, Benign Mucous Membrane (Phase 3)

Pemphigoid, Bullous (Phase 4)

Pemphigus (Phase 3)

Placenta Previa (Phase 2)

Pneumonia (Phase 2)

Polymyalgia Rheumatica (Phase 3)

Premature Birth (Phase 4)

Prolapse (Phase 3)

Psoriasis (Phase 3)

Psychomotor Agitation (Phase 3)

Renal Insufficiency (Phase 3)

Renal Insufficiency, Chronic (Phase 1)

Retinal Neoplasms (Phase 2)

Retinoblastoma (Phase 2)

Shock (Phase 3)

Shock, Septic (Phase 3)

Stomatitis (Phase 3)

Stomatitis, Aphthous (Phase 3)

Syndrome (Phase 2)

Urinary Bladder Neoplasms (Phase 3)

Urinary Bladder, Overactive (Phase 2)

Urticaria (Phase 4)

Vision Disorders (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 92
  • # of Trial APIs: 110